A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
Study sponsor: Zai Lab (Shanghai) Co., Ltd.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-02-26Actual
Enrollment · participants39Actual
Source updated2025-03-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.